{
    "name": "tenapanor",
    "comment": "Rx",
    "other_names": [
        "Ibsrela"
    ],
    "classes": [
        "IBS Agents",
        "Sodium/Hydrogen Exchanger 3 (NHE3) Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/ibsrela-tenapanor-1000311",
    "pregnancy": {
        "common": [
            "Tenapanor is minimally absorbed systemically, with plasma concentrations below the limit of quantification",
            "Maternal use is not expected to result in fetal drug exposure"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Data are not available regarding the presence in either human or animal milk, its effects on milk production, or its effects on the breastfed infant",
            "The minimal systemic absorption of tenapanor will not result in a clinically relevant exposure to breastfed infants"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Contraindicated in patients aged <6 years",
                "Studies in young juvenile rats administered tenapanor reported deaths related to dehydration",
                "Avoid use in patients aged 6 to <12 yr",
                "Safety and effectiveness not established in patients aged <18 yr"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Children aged <6 years owing to risk of serious dehydration",
                "Known or suspected mechanical GI obstruction"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Diarrhea may occur; if severe, suspend dosing and rehydrate patient",
                "Contraindicated in children aged <6 yr; avoid use in children aged 6-12 yr owing to risk of dehydration in young children"
            ],
            "specific": [
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Inhibitor of intestinal uptake transporter, OATP2B1",
                        "OATP2B1 substrates",
                        "Monitor for signs related to loss of efficacy and adjust OATP2B1 substrate dose accordingly ",
                        "Tenapanor may reduce systemic exposure of OATP2B1 substrates ",
                        "When enalapril was coadministered with tenapanor (30 mg PO BID for 5 days, a dosage 0.6x the recommended dosage), peak exposure of enalapril and its active metabolite, enalaprilat, decreased by ~70% and total systemic AUC decreased by ~50- 65% compared to when enalapril was administered alone ",
                        "Monitor blood pressure and increase dosage of enalapril, if needed"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atorvastatin",
            "description": {
                "common": "tenapanor decreases levels of atorvastatin by Other (see comment). Use Caution/Monitor. \nComment: Tenapanor (an inhibitor of intestinal uptake transporter, OATP2B1) may reduce the exposure of OATP2B1 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bosentan",
            "description": {
                "common": "tenapanor decreases levels of bosentan by Other (see comment). Use Caution/Monitor. \nComment: Tenapanor (an inhibitor of intestinal uptake transporter, OATP2B1) may reduce the exposure of OATP2B1 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "conjugated estrogens",
            "description": {
                "common": "tenapanor decreases levels of conjugated estrogens by Other (see comment). Use Caution/Monitor. \nComment: Tenapanor (an inhibitor of intestinal uptake transporter, OATP2B1) may reduce the exposure of OATP2B1 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "enalapril",
            "description": {
                "common": "tenapanor decreases levels of enalapril by Other (see comment). Modify Therapy/Monitor Closely. \nComment: Tenapanor inhibits intestinal uptake transporter, OATP2B1; peak exposure (Cmax) of enalapril and its active metabolite, enalaprilat, decreases significantly when both drugs administered concomitantly; monitor blood pressure and increase dosage of enalapril, if needed, when coadministered with this drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fexofenadine",
            "description": {
                "common": "tenapanor decreases levels of fexofenadine by Other (see comment). Use Caution/Monitor. \nComment: Tenapanor (an inhibitor of intestinal uptake transporter, OATP2B1) may reduce the exposure of OATP2B1 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluvastatin",
            "description": {
                "common": "tenapanor decreases levels of fluvastatin by Other (see comment). Use Caution/Monitor. \nComment: Tenapanor (an inhibitor of intestinal uptake transporter, OATP2B1) may reduce the exposure of OATP2B1 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glyburide",
            "description": {
                "common": "tenapanor decreases levels of glyburide by Other (see comment). Use Caution/Monitor. \nComment: Tenapanor (an inhibitor of intestinal uptake transporter, OATP2B1) may reduce the exposure of OATP2B1 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pravastatin",
            "description": {
                "common": "tenapanor decreases levels of pravastatin by Other (see comment). Use Caution/Monitor. \nComment: Tenapanor (an inhibitor of intestinal uptake transporter, OATP2B1) may reduce the exposure of OATP2B1 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rosuvastatin",
            "description": {
                "common": "tenapanor decreases levels of rosuvastatin by Other (see comment). Use Caution/Monitor. \nComment: Tenapanor (an inhibitor of intestinal uptake transporter, OATP2B1) may reduce the exposure of OATP2B1 substrates."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Diarrhea",
            "percent": "15-16"
        },
        {
            "name": "Abdominal distension",
            "percent": "2-3"
        },
        {
            "name": "Flatulence",
            "percent": "3"
        },
        {
            "name": "Severe diarrhea",
            "percent": "2.5"
        },
        {
            "name": "Dizziness",
            "percent": "2"
        },
        {
            "name": "Rectal bleeding",
            "percent": "2"
        },
        {
            "name": "Abnormal GI sounds",
            "percent": "2"
        }
    ]
}